Narcolepsy: Diagnosis and Management

Principles and Practice of Sleep Medicine: Fifth Edition

Volumn , Issue , 2010, Pages 957-968

  Guilleminault, Christian ^a   Cao, Michelle T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859044189     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6645-3.00085-2     Document Type: Chapter

References (95)

1. Gélineau J De la narcolepsie. Gaz Hop (Paris) 1880, 53:626-628. 1880;54:635-737.
2. Westphal C Eigenthümliche mit Einschläfen verbundene Anfälle. Arch Psychiatr 1677, 7:631-635.
3. Fisher F Epileptoide schlafzustände. Arch Psychiatr 1878, 8:200-203.
4. Henneberg R Über genuine Narkolepsie. Neurol Zbl 1916, 30:282-290.
5. Daniels L Narcolepsy. Medicine (Baltimore) 1934, 13:1-122.
6. Yoss RE, Daly DD Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin 1957, 32:320-328.
7. Vogel G Studies in the psychophysiology of dreams: III. The dream of narcolepsy. Arch Gen Psychiatry 1960, 3:421-425.
8. Rechtschaffen A, Wolpert E, Dement WC, et al. Nocturnal sleep of narcoleptics. Electroencephalogr Clin Neurophysiol 1963, 15:599-609.
9. Takahashi Y, Jimbo M Polygraphic study of narcoleptic syndrome with special reference to hypnagogic hallucinations and cataplexy. Folia Psychiatr Neurol Jpn 1963, 7(Suppl.):343-347.
10. Passouant P, Schwab RS, Cadilhac J, et al. Narcolepsie-cataplexie: Etude du sommeil de nuit et du sommeil de jour. Rev Neurol (Paris) 1964, 3:415-426.
11. Hishikawa Y, Kaneko Z Electroencephalographic study on narcolepsy. Electroencephalogr Clin Neurophysiol 1965, 18:249-258.
12. Rosen GM, Bendel AE, Neglia JP, et al. Sleep in children with neoplasms of the central nervous system: case review of 14 children. Pediatrics 2003, 112:e46-e54.
13. Broughton R, Valley V, Aguirre M, et al. Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep 1986, 9:205-215.
14. American Academy of Sleep Medicine International classification of sleep disorders: diagnostic and coding manual 2005, American Academy of Sleep Medicine, Westchester, Ill. 2nd ed.
15. Brooks S, Mignot E Narcolepsy and idiopathic hypersomnia. Sleep medicine 2002, 193-202. Hanley & Belfus, Philadelphia. T. Lee-Chiong, M. Sateia, M. Carskadon (Eds.).
16. Bassetti C, Aldrich MS Narcolepsy. Neurol Clin 1996, 14(3):545-571.
17. Szucs A, Janszky J, Hollo A, et al. Misleading hallucinations in unrecognized narcolepsy. Acta Psychiatr Scand 2003, 108:314-316.
18. Guilleminault C, Pelayo R Narcolepsy in prepubertal children. Ann Neurol 1998, 43:135-142.
19. Ohayon MM, Ferini-Strambi L, Plazzi G, et al. How age influences the expression of narcolepsy. J Psych Psychosom Res 2005, 59:399-405.
20. Morrish E, King MA, Smith IE, et al. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 2004, 5:37-41.
21. Ohayon MM, Priest RG, Caucet M, et al. Hypnagogic and hypnopompic hallucinations: pathological phenomenon?. Br J Psychiatry 1996, 169:459-467.
22. Billiard M, Besset A, Cadilhac J The clinical and polygraphic development of narcolepsy. Sleep/wake disorders: natural history, epidemiology, and long term evolution 1983, 187-199. Raven Press, New York. C. Guilleminault, E. Lugaresi (Eds.).
23. Schmidt HS, Fortin LD Electronic pupillography in disorders of arousal. Sleep and waking disorders: indications and techniques 1981, 127-141. Addison-Wesley, Menlo Park, Calif. C. Guilleminault (Ed.).
24. Hoddes E, Dement WC, Zarcone V The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiology 1972, 9:150.
25. Carskadon MA, Dement WC The multiple sleep latency test: what does it measure?. Sleep 1982, 5:67-72.
26. Rechtschaffen A, Kales AD A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects 1968, UCLA Brain Information Service/Brain Research Institute, Los Angeles.
27. Association of Professional Sleep Societies, APSS Guidelines Committee Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986, 9:519-524.
28. Van den Hoed J, Kraemer H, Guilleminault C, et al. Disorders of excessive daytime somnolence: polygraphic and clinical data for 100 patients. Sleep 1981, 4:23-38.
29. Browman CP, Gujavarty KS, Sampson MG, et al. REM sleep episodes during the maintenance of wakefulness tests in patients with sleep apnea syndrome and patients with narcolepsy. Sleep 1983, 6:23-28.
30. Dauvilliers Y, Gosselin A, Paquet J, et al. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 2004, 62:46-50.
31. HLA in narcolepsy 1988, Springer-Verlag, Berlin. Y. Honda, T. Juji (Eds.).
32. Singh M, Drake CL, Roth T The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 2006, 29(7):890-895.
33. Anic-Labat S, Guilleminault C, Kraemer HC, et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999, 22:77-87.
34. Moscovitch A, Partinen M, Patterson N, et al. Cataplexy in differentiation of excessive daytime somnolence. Sleep Res 1991, 20:301.
35. Mignot E, Hayduk R, Black J, et al. HLA-DQB1*0602 is associated with narcolepsy in 509 narcoleptic patients. Sleep 1997, 20:1012-1020.
36. Zeman A, Britton T, Douglas N, et al. Narcolepsy and excessive daytime sleepiness. BMJ 2004, 329:724-728.
37. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
38. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322-327.
39. Dauviliers Y, Arnulf I, Mignot E Narcolepsy with cataplexy. Lancet 2007, 369:499-511.
40. Lin L, Faraco R, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
41. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
42. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998, 18:9996-10015.
43. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
44. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
45. Zaharna M, Dimitriu A, Guilleminault C Expert opinion on pharmacotherapy of narcolepsy. Expert Opin Pharmacother 2010, 11:1633-1645.
46. Guilleminault C Amphetamines and narcolepsy: use of Stanford database. Sleep 1993, 16:199-201.
47. Broughton R, Mamelak M The treatment of narcolepsy-cataplexy with nocturnal gamma hydroxybutyrate. Can J Neurol Sci 1979, 6:1-6.
48. Scharf MB, Brown D, Woods M, et al. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychol 1985, 46:222-225.
49. Lammers GJ, Arends J, Declerck AC, et al. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993, 16:216-220.
50. Mamelak M, Scharf MB, Woods M Treatment of narcolepsy with gamma-hydroxybutyrate: a review of clinical and sleep laboratory findings. Sleep 1986, 9:285-289.
51. U.S.Xyrem Multicenter Study Group A randomized, double blind, multicenter trial comparing the effect of 3 doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002, 25:42-49.
52. Borgen LA, Okerholm RA, Lai A, et al. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 2004, 44:253-257.
53. U.S.Xyrem Multicenter Study Group Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004, 5:119-123.
54. A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002, 25:42-49.
55. Scharf MB Assessment of sodium oxybate for the long-term treatment of narcolepsy. Sleep 2001, 23(Abstract Suppl.):A234.
56. U.S.Xyrem Multicenter Study Group A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003, 26:31-35.
57. Hornfeltdt C, Pertile T Lack of withdrawal symptoms following abrupt cessation of therapeutically administered sodium oxybate. Sleep 2001, 24(Abstract Suppl.):A236.
58. Black J, Ristanovic R, Mamelak M, et al. Dose response effects of sodium oxybate on polysomnographic (PSG) measures in narcolepsy patients; preliminary findings. Sleep 2001, 24(Abstract Suppl.):A321.
59. Hayduk R, Mitler MM Sodium oxybate therapy improves the quality of life of narcolepsy patients. Sleep 2001, 24(Abstract Suppl.):A326.
60. Ristanovic RA, Black J, Mamelak M, et al. Effect of increasing doses of sodium oxybate on nocturnal respiratory disturbances. Sleep 2002, 25(Abstract Suppl.):A473-A474.
61. Black J, Ristanovic RA, Mamelak M, et al. Effect of increasing doses of sodium oxybate on nocturnal oxygen saturation: preliminary findings. Sleep 2002, 25(Abstract Suppl.):A474-A475.
62. Billiard M Narcolepsy: current treatment options and future approaches. Neuropsych Dis Treatment 2008, 4:557-566.
63. Roth T Narcolepsy: treatment issues. J Clin Psych 2007, 68(Suppl. 13):16-19.
64. Golicki D, Bala MM, Niewada M, Wierzbicka A Modafinil for narcolepsy: systematic review and meta-analysis. Med Sci Monit 2010, 16:RA177-186.
65. Boutrel B, Koob GF What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004, 27:1181-1194.
66. Wisor J, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21:1787-1794.
67. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 15:436-437.
68. Parkes JD, Dahlitz M Amphetamine prescription. Sleep 1993, 16:201-203.
69. Bogan RK Armodafinil in the treatment of excessive sleepiness. Expert Opin Pharmacother 2010, 11:993-1002.
70. Lankford DA Armodafinil: a new treatment for excessive sleepiness. Expert Opin Investig Drugs 2008, 17:565-573.
71. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006, 22:761-774.
72. Prinzmetal M, Bloomberg W The use of benzedrine for treatment of narcolepsy. JAMA 1935, 105:2051-2054.
73. Mitler M, Erman M, Hajdukovic R The treatment of excessive somnolence with stimulant drugs. Sleep 1993, 16:203-206.
74. Black J, Houghton WC Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006, 29:939-946.
75. Fry JM Treatment modalities for narcolepsy. Neurology 1998, 50(Suppl. 1):S43-S48.
76. Akimoto H, Honda Y, Takahashi Y Pharmacotherapy in narcolepsy. Diseases of the nervous system 1960, 21:1-3.
77. Hishikawa Y, Ida H, Nakai K, et al. Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J Neurol Sci 1965, 3:453-461.
78. Schmidt HS, Clark RW, Hyman PR Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977, 134:183-185.
79. Langdon N, Bandak S, Shindler J, et al. Fluoxetine in the treatment of cataplexy. Sleep 1986, 9:371-372.
80. Cao M Advances in Narcolepsy. Med Clin North Am 2010, 94(3):541-555.
81. Nishino S, Okuro M Emerging treatments for narcolepsy and its related disorders. Expert Opin Emerg Drugs 2010, 15:139-158.
82. Deadwyler SA, Porrino L, Siegel JM, et al. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007, 27:14239-14247.
83. Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649-4654.
84. Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997, 17:6401-6408.
85. Le S, Gruner JA, Mathiasen JR, et al. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp 2008, 325:902-909.
86. Parmentier R, Anaclet C, Guhennec C, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 2007, 73:1157-1171.
87. Shiba T, Fujiki N, Wisor JP, et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2004, 27(Abstract Suppl.):S241-S242.
88. Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of high-dose intravenous immunoglobins near the onset of narcolepsy in a 10-year old boy. J Sleep Res 2003, 12:347-348.
89. Hecht M, Ling L, Kushida C, et al. Report of a case of immunosuppression with prednisone in an 8-year old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003, 26:809-810.
90. Bedart MA, Montplaisir J, Godbout R Effect of l-dopa on periodic movements in sleep in narcoleptics. Eur Neurol 1987, 27:35-38.
91. Boivin MA, Montplaisir J, Poirier G The effect of l-dopa on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol 1989, 12:29-37.
92. Parkes JD Amphetamines and alertness. Narcolepsy 1976, 643-657. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
93. Ivanenko A, Tauman R, Gozal D Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003, 4:579-582.
94. Yoss RE, Daly DD Treatment of narcolepsy with Ritalin. Neurology 1959, 9:171-173.
95. Guilleminault C, Pelayo R Narcolepsy in children: a practical guide to its diagnosis, treatment, and follow-up. Paediatr Drugs 2000, 2:1-9.